0.3975
Schlusskurs vom Vortag:
$0.3702
Offen:
$0.37
24-Stunden-Volumen:
732.02K
Relative Volume:
1.45
Marktkapitalisierung:
$24.67M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-126.61M
KGV:
-0.2028
EPS:
-1.96
Netto-Cashflow:
$-60.14M
1W Leistung:
-13.00%
1M Leistung:
-25.99%
6M Leistung:
-83.30%
1J Leistung:
-90.35%
Generation Bio Co Stock (GBIO) Company Profile
Firmenname
Generation Bio Co
Sektor
Branche
Telefon
857-529-5908
Adresse
301 BINNEY STREET, CAMBRIDGE
Vergleichen Sie GBIO mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
GBIO
Generation Bio Co
|
0.3975 | 24.67M | 0 | -126.61M | -60.14M | -1.96 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 125.55B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 67.78B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
590.06 | 36.24B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.99B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
264.32 | 28.77B | 3.81B | -644.79M | -669.77M | -6.24 |
Generation Bio Co Stock (GBIO) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2023-10-19 | Herabstufung | TD Cowen | Outperform → Market Perform |
2022-11-08 | Eingeleitet | Canaccord Genuity | Buy |
2021-12-14 | Herabstufung | William Blair | Outperform → Mkt Perform |
2021-06-08 | Eingeleitet | JMP Securities | Mkt Outperform |
2021-02-24 | Eingeleitet | William Blair | Outperform |
2021-02-18 | Eingeleitet | Needham | Buy |
2020-07-07 | Eingeleitet | Cowen | Outperform |
2020-07-07 | Eingeleitet | JP Morgan | Overweight |
2020-07-07 | Eingeleitet | Jefferies | Buy |
2020-07-07 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Generation Bio Co Aktie (GBIO) Neueste Nachrichten
Generation Bio stock hits 52-week low at $0.4 amid steep decline - Investing.com Australia
Generation Bio to Present at the Needham 24th Annual Virtual Healthcare Conference - The Manila Times
Generation Bio Takes Center Stage: CEO Fireside Chat at Major Healthcare Conference - Stock Titan
Charles Schwab Investment Management Inc. Cuts Stake in Generation Bio Co. (NASDAQ:GBIO) - Defense World
Layoff Tracker: Arbutus Cuts 57% of Workforce - BioSpace
Generation Bio Co. (GBIO) Reports Q4 Loss, Tops Revenue Estimates - MSN
Generation Bio stock hits 52-week low at $0.47 By Investing.com - Investing.com South Africa
Generation Bio stock hits 52-week low at $0.47 - Investing.com
Generation Bio’s (GBIO) Buy Rating Reaffirmed at Canaccord Genuity Group - Defense World
Generation Bio’s SWOT analysis: stock pivots to T-cell focus amid market caution By Investing.com - Investing.com South Africa
Generation Bio’s SWOT analysis: stock pivots to T-cell focus amid market caution - Investing.com Australia
Generation Bio’s (GBIO) Outperform Rating Reiterated at Wedbush - Defense World
Generation Bio Co. (NASDAQ:GBIO) Not Doing Enough For Some Investors As Its Shares Slump 29% - Simply Wall St
Generation Bio Co. Advances in Autoimmune Therapeutics - TipRanks
Generation Bio Co reports results for the quarter ended December 31Earnings Summary - TradingView
Generation Bio stock holds Market Perform rating at JMP - Investing.com India
Generation Bio stock holds Market Perform rating at JMP By Investing.com - Investing.com UK
Generation Bio earnings missed by $0.02, revenue topped estimates - Investing.com South Africa
Generation Bio Co (GBIO) Q4 2024 Earnings: EPS Misses Estimate o - GuruFocus.com
Generation Bio Reports Business Highlights and Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
Generation Bio Co. Advances T Cell-Selective siRNA Therapeutics for Autoimmune Diseases, Announces Robust Financial Position - Nasdaq
Generation Bio's Breakthrough: 98% T Cell Success Powers $185M Cash Runway Through 2027 - StockTitan
Generation Bio Co (GBIO)’s stock rises to 0.52 per share - US Post News
Generation Bio stock hits 52-week low at $0.52 By Investing.com - Investing.com Australia
A Guide To The Risks Of Investing In Generation Bio Co (GBIO) - Knox Daily
Generation Bio stock hits 52-week low at $0.52 - Investing.com
Generation Bio (GBIO) Expected to Announce Quarterly Earnings on Wednesday - Defense World
Contrasting Generation Bio (NASDAQ:GBIO) & Anthera Pharmaceuticals (OTCMKTS:ANTH) - Defense World
Generation Bio faces Nasdaq delisting over share price By Investing.com - Investing.com Canada
Generation Bio faces Nasdaq delisting over share price - Investing.com India
Generation Bio to Present at the TD Cowen 45th Annual Health Care Conference - The Manila Times
Can Generation Bio's Autoimmune Disease Strategy Transform T Cell Treatment? CEO Reveals Plans - StockTitan
Kineticos Launches Kinvard Bio to Advance Next-Generation Antibiotics in the Fight Against Antimicrobial Resistance - PR Newswire
Generation Bio stock hits 52-week low at $0.6 amid sharp decline - Investing.com Nigeria
Generation Bio stock hits 52-week low at $0.6 amid sharp decline By Investing.com - Investing.com South Africa
Spore.Bio raises €22 million to deploy a new generation of AI-based microbiology testing - EU-Startups
Finanzdaten der Generation Bio Co-Aktie (GBIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):